Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina Bachmeier

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Therapeutic Advances in Hematology|April 26, 2019
CAR T-cell therapy for B-cell lymphomas: clinical trial results of available productsJulio C Chavez, Christina Bachmeier, Mohamed A Kharfan-Dabaja
Transplantation and Cellular Therapy|April 28, 2021
Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient AdministrationMaurice Alexander, Kathryn Culos, Julianna Roddy, et al.
Transplantation and Cellular Therapy|June 2, 2021
Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell LymphomaAlbert Cortes-Bullich, Ariel Perez, Christina Bachmeier, et al.
Transplantation and Cellular Therapy|March 6, 2023
Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular LymphomaNing Dong, Lucía Rubio Lopes-Garcia, David Viñal, et al.
International Journal of Radiation Oncology, Biology, Physics|July 9, 2021
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell TherapyNicholas B Figura, Timothy J Robinson, Austin J Sim, et al.
Transplantation and Cellular Therapy|March 30, 2021
Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell LymphomaAbu-Sayeef Mirza, Ambuj Kumar, Hamza Hashmi, et al.
Cardio-Oncology (London, England)|April 3, 2023
Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory studyDae Hyun Lee, Sanjay Chandrasekhar, Michael D Jain, et al.
Science Advances|September 22, 2023
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansionKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Blood|January 29, 2021
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphomaMichael D Jain, Hua Zhao, Xuefeng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2025
Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell LymphomaKhushali Jhaveri, Ram Thapa, Dalia Ercan, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Therapeutic Advances in Hematology|April 26, 2019
CAR T-cell therapy for B-cell lymphomas: clinical trial results of available productsJulio C Chavez, Christina Bachmeier, Mohamed A Kharfan-Dabaja
Transplantation and Cellular Therapy|April 28, 2021
Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient AdministrationMaurice Alexander, Kathryn Culos, Julianna Roddy, et al.
Transplantation and Cellular Therapy|June 2, 2021
Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell LymphomaAlbert Cortes-Bullich, Ariel Perez, Christina Bachmeier, et al.
Transplantation and Cellular Therapy|March 6, 2023
Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular LymphomaNing Dong, Lucía Rubio Lopes-Garcia, David Viñal, et al.
International Journal of Radiation Oncology, Biology, Physics|July 9, 2021
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell TherapyNicholas B Figura, Timothy J Robinson, Austin J Sim, et al.
Transplantation and Cellular Therapy|March 30, 2021
Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell LymphomaAbu-Sayeef Mirza, Ambuj Kumar, Hamza Hashmi, et al.
Cardio-Oncology (London, England)|April 3, 2023
Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory studyDae Hyun Lee, Sanjay Chandrasekhar, Michael D Jain, et al.
Science Advances|September 22, 2023
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansionKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Blood|January 29, 2021
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphomaMichael D Jain, Hua Zhao, Xuefeng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2025
Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell LymphomaKhushali Jhaveri, Ram Thapa, Dalia Ercan, et al.
Pageof 2